Jan, 2022

Global
News / General News
We posted the presentation material for media briefing on Digital Transformation of Astellas Pharma.
Read More

Dec, 2021

Global
News / Press Releases
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
- If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-based chemotherapy and a PD-1/L1 inhibitor - TOKYO and BOTHELL, Wash. – December 17, 2021 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
Read More
Global
News / General News
Astellas Updates “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...
Read More
Global
News / General News
Astellas Changes its Corporate Website Structure
We announce the changes to our corporate website as follows. Integration of the corporate website Before: Global site (English) and Japan site (English and Japanese) After: Global site (English) and Japan site (Japanese) Reason for change: The content on the Global site and the Japan site (English) were a duplicate, and so a decision was made to integrate the content by changing the structure...
Read More
Global
News / IR
Updated “R&D meeting” Section
Read More

Dec, 2021

Global
News / Press Releases
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
- If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-based chemotherapy and a PD-1/L1 inhibitor - TOKYO and BOTHELL, Wash. – December 17, 2021 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
Read More
Global
News / Press Releases
Astellas Applied for Selection of “Prime Market” segment of the Tokyo Stock Exchange
TOKYO, December 6 , 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today applied for selection of the “Prime Market” segment of the Tokyo Stock Exchange, Inc. (“TSE”) as its listing market as determined at the Board of Directors Meeting held on November 19, 2021. Astellas received the results of the initial assessment made by the TSE on July 9, 2021...
Read More
Global
News / Press Releases
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
- Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion - TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., “Dyno”) today announced an option and license agreement was signed on November...
Read More
Global
News / Press Releases
Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia – from Diagnosis to Relapse – at 2021 American Society of Hematology Annual Meeting
• Four AML oral presentations are among highest number of Astellas-sponsored ASH abstracts to date • Full results of Phase 3 LACEWING, COMMODORE trials will be presented • Oral presentation explores potential sickle cell disease treatment pathway TOKYO, Dec. 1, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new...
Read More

Nov, 2021

Global
News / Press Releases
Astellas and Pantherna Enter into Technology Evaluation Agreement for Research of mRNA-based Regenerative Medicine
TOKYO and Hennigsdorf, Germany, November 15, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pantherna Therapeutics GmbH (CEO: Klaus Giese, Ph.D., “Pantherna”) today announced that the companies have entered into a technology evaluation agreement for the research of mRNA-based regenerative medicine. Pantherna has a technology platform consisting of...
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match.

News